TheraVet Announces the Launch of the Pivotal European Multicentric Clinical Study of VISCO-VET in Canine Osteoarthritis

• Pivotal clinical trial of VISCO-VET in canine osteoarthritis approved in France and Netherlands
• First investigating site initiated in France
• Start of patients enrolment anticipated in October 2021

JUMET, Belgium--(BUSINESS WIRE)--Regulatory News:

TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces the launch of the pivotal European multicentric clinical study assessing VISCO-VET in canine osteoarthritis.

VISCO-VET, TheraVet’s viscoregenerative gel, will be assessed in a prospective, multicentric, controlled, double-blinded, randomized, pivotal field study in client-owned dogs suffering from osteoarthritis (OA). The study will evaluate the potential of a unique intra-articular injection of VISCO-VET in stifle or elblow to improve dog’s mobility and reduce pain compared to a non-treated control group. Patients will be followed for 3 months.

In the study, 154 client-owned dogs with osteoarthritis will be enrolled. The study will be conducted in 20 centers in four (4) countries including France, Netherlands, Portugal and Poland. The Company has received the approval in France and Netherlands and has just started the initiation of the investigating sites in these countries. The approval in the remaining territories is expected to be obtained in the following weeks. First patient treated is expected in October 2021.

An update on patients recruitment will be provided in the second quarter of 2022, following by top-line interim analyses results.

Enrico Bastianelli, Chief Executive Officer of TheraVet, concludes: “Following the positive efficacy and safety results of VISCO-VET in the proof-of-concept study, we are very delighted to initiate the patient recruitment of this pivotal trial for VISCO-VET.”

About TheraVet SA

TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris et Brussels, its head office is in Jumet, Belgium, and it has a subsidiary in the US.

For more information, visit the TheraVet website

Or follow us on LinkedIn / Facebook / Twitter

TheraVet
Sabrina Ena
Chief Operating Officer
Sabrina.ena@thera.vet
Tel: +32 (0) 71 18 32 49

Julie Winand
Chief Corporate Officer
julie.winand@thera.vet
Tel: +32 (0) 71 18 32 49

NewCap
Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud
theravet@newcap.eu
Tel: +33 (0)1 44 71 94 94

Press Relations
Arthur Rouillé / Ambre Delval
theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15